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Metformin (1,1-dimethylbiguanide) is an anti-hyperglycemic agent that is commonly used in the 
oral treatment of Type 2 Diabetes Mellitus. Phenformin (phenethylbiguanide) is its structural 
analog. As an anti-hyperglycemic agent, metformin is known to affect glucose transporters. 
Lactobacillus acidophilus is a bacteria that ferments lactic acid under anaerobic conditions and 
is known to contain numerous glucose transporters. Inconclusive results were seen during NMR 
analysis due to the lack of lactic acid and the increase of glucose over time. With completely 
anaerobic conditions and longer measurement periods, it is hopeful that further 
experimentation will be successful. Adenosine deaminase is involved in purine nucleoside 
metabolism. Based on molecular docking simulations, we have hypothesized that adenosine 
deaminase could be inhibited by metformin and phenformin, and that phenformin is a better 
inhibitor than metformin. The inhibitory effect of metformin and phenformin on adenosine 
deaminase from bovine spleen was studied spectrophotometrically. Non-linear regression 
analysis was used to obtain the inhibition constants. Metformin was a competitive inhibitor of 
deamination of adenosine with the inhibition constant, KI, of 88 mM. Phenformin was slightly 
more effective than metformin as a competitive inhibitor with KI of 10 mM. The KM of 
adenosine was 31 μM. The inhibition constant values indicate that neither metformin nor 
phenformin is a potent inhibitor of adenosine deaminase. It is unlikely that at the physiological 









Diabetes Mellitus is an increasingly prevalent disease that affects an estimated 25.8 million 
people in the United States alone.1 The majority of these people are diagnosed as having Type 2 
Diabetes Mellitus (T2DM). T2DM is characterized by insulin resistance resulting in abnormally 
high blood glucose levels due to the inability of glucose uptake by cells.2 Along with careful 
regulation and monitoring of blood glucose levels, T2DM patients can also be prescribed other 
treatment options, such as metformin. Metformin is a biguanide, antihyperglycemic agent that 
is known to lower blood glucose concentration, increase glucose uptake in cells, and improve 
insulin sensitivity.3 Phenformin was another treatment option similar to metformin, until it was 
taken off the market due to problems associated with lactic acidosis.4 
   
          Figure 1: Structure of Metformin           Figure 2: Structure of Phenformin 
There are several proposed mechanisms associated with the specific functioning of metformin 
within Type 2 Diabetics. The most commonly accepted mechanisms involve the inhibition of 
AMP deaminase (AMPD), an enzyme the converts AMP into IMP, and mitochondrial complex 1, 
an enzyme in the electron transport chain. Together, the inhibition of both of these enzymes 
essentially increase the concentration of AMP, stimulating AMP-activated protein kinase 
(AMPK).3 Activation of AMPK causes the inhibition of synthetic pathways including 
gluconeogenesis and fatty acid synthesis; and, the stimulation of catabolic pathways including 
glucose degradation and β-oxidation.3 Adenosine deaminase (ADA), an enzyme that converts 
adenosine into inosine, has a similar function as AMPD.5 Comparatively speaking, researching 
the inhibition of ADA by metformin will help extrapolate inhibition of AMPD. Molecular docking 
simulations, seen below, show that metformin will bind tightly and similarly to adenine at the 
active site on ADA. 
                       
 Figure 3: Metformin bound to ADA Figure 4: Adenine bound to ADA 
In addition to studying the effects of metformin on certain enzymes, glucose transporters were 
also studied using Lactobacillus acidophilus, a bacterium primarily functioning to ferment sugar 
into lactic acid.6 Since this bacterium is known to metabolize glucose into lactic acid, its 
membrane contains numerous glucose transporters.6 In general, metformin increases uptake of 
glucose in cells; however, it is unclear exactly how metformin interacts mechanistically with 
glucose transporters.  
 
EXPERIMENTAL PROCEDURE 
To study glucose transporters, Lactobacillus acidophilus 4365 and its recommended growth 
media 416 was purchased from ATCC. The Lactobacilli MRS broth (BD 288130) was made using 
55 grams/ 1 L. A total of 2 Liters of broth was made and autoclaved at 121 degrees Celsius to 
ensure sterility. A small sample of 24 hour incubation cells were prepared at 80 rpm at 35.5 
degrees Celsius. The broth was a dark brown color, when cells started growing the broth-cell 
solution turned a lighter brown color and had a cloudy appearance. Next, the rate of bacterial 
growth was measured over time using a broth sample as the standard auto-zero. The cells from 
the 24 hour incubation small sample were measured to have an absorbance of 1.61 at 600 nm 
wavelength using UV-vis spectroscopy. Bacterial growth measurements were taken from 
samples prepared with 25 mL MRS broth to 1 mL of small sample incubation cells every 30 
minutes until growth increase plateaued based on the absorbance values at 600 nm. Growth 
was slow but leveled off around 14 hours; the primary growth slope took approximately 10 
hours as seen in the Graph below. A large culture of Lactobacillus acidophilus was then made 
using this timeframe at the same incubation settings.  
The cells were centrifuged at 1500 rpm for 10 minutes and the supernatant was discarded. 10 
mL of Buffer A was added per gram of cell; there was 1.457 grams of cells so 14.57 mL of buffer 
was added. The cells were combined into the same test tube and the following solutions were 
made according to Table 1 and Table 2. The solutions were vortexed and incubated for the 
allotted time (Note that 0 minutes indicates the cells should be killed immediately).  
 
Table 1: Control Solutions 
Tube Cell Suspension 
(mL) 





1 1 0.025 0.025 0 
2 1 0.025 0.025 2 
3 1 0.025 0.025 4 
4 1 0.025 0.025 6 
5 1 0.025 0.025 8 
6 1 0.025 0.025 10 
 
Table 2: Metformin Solutions 









1 1 0.025 0.025 0 
2 1 0.025 0.025 2 
3 1 0.025 0.025 4 
4 1 0.025 0.025 6 
5 1 0.025 0.025 8 
6 1 0.025 0.025 10 
 
After the incubation time is complete, the cells were killed with 0.125 mL of 70% perchloric 
acid. The cells were then broken up by freezing each tube in liquid nitrogen and thawing in 
water bath three times. Then, the solutions were centrifuged at 2,000 rmp for 2 minutes. 0.145 
mL of 10M KOH was added to the solution for neutralization. Then, 0.122 mL D2O was added 
and the tubes were centrifuged at 5,000 rpm for two minutes in order to remove any 
precipitates. The supernatant was then removed using a pipet, making sure not to disturb the 
pellet, and transferred into a clean NMR tube. The 13C NMR was done using D2O for locking and 
100 proton-decoupled scans per spectrum were collected.  
In the next experiment, the inhibition of ADA obtained from bovine spleen by anti-
hyperglycemic agents metformin and phenformin was studied. The activity of ADA was 
measured through continuous spectrophotometric rate determination via UV-vis 
spectrophotometer at a 265 nm wavelength. Quartz cuvettes containing a 50 mM phosphate 
buffer at pH 7.4 and adenosine concentrations ranging from 15 µM to 133 µM provided a 
control group. Metformin was studied at concentrations of 10 mM, 20 mM, and 40 mM while 
phenformin was studied at concentrations of 2 mM, 3.3 mM, 4 mM, and 30 mM. All chemicals 
used in these reactions were purchased from Sigma-Aldrich. The data obtained was used to 
calculate ADA activity and was used to create a nonlinear regression graph. Through non-linear 
regression analysis of these graphs, calculations of Vmax, Km, and KI were carried out in order to 
help characterize the type of inhibition metformin and phenformin present on adenosine 
deaminase. 
It is important to note that this report was done to describe the experiments pertaining to 
glucose transporters in Lactobacillus acidophilus. The adenosine deaminase experiment was 
included to help describe further experiments done on a similar topic that help in 
understanding and analyzing this particular research experiment.  
 
 
RESULTS AND DISCUSSION 
 
Graph 1: Growth Rate of Lactobacillus acidophilus as a Function of Absorbance 
 
 
Table 3: NMR Data for Control Solutions 
 β-Glucose α-Glucose 
Time Peak (ppm) Peak Height 
[abn] 
Peak (ppm) Peak Height 
[abn] 
0 96.0 0.75183 92.2 0.41317 
2 96.0 1.35312 92.2 0.6978 
4 95.9 1.10188 92.17 0.6444 
6 95.9 1.21526 92.17 0.69443 
8 95.9 1.07791 92.18 0.57009 




Table 4: NMR Data for Metformin Solutions 
 β-Glucose α-Glucose 
Time Peak (ppm) Peak Height 
[abn] 
Peak (ppm) Peak Height 
[abn] 
0 96.0 1.44792 92.1 0.81084 
2 95.9 1.23372 92.1 0.63353 
4 95.8 0.74083 92.1 0.30322 
6 95.7 0.71139 92.0 0.25662 
8 95.9 1.13356 92.17 0.61201 




























Spectra 2: Sample 6 NMR spectrum 
 
Spectra 3: Sample 11 NMR spectrum 
 
 
Spectra 4: Sample 16 NMR spectrum 
 
 
Graph 2: Peak Height vs. Incubation Time for Beta Glucose 
 
 

















































Alpha Glucose Consumption Over Time
Control A Glucose
Metformin A Glucose
The data seen above shows inconclusive results. All spectra analyzed showed peaks around 96 
ppm and 92 ppm. Using the Spectral Database for Organic Compounds SDBS, it was determined 
that the peak at 96 ppm represents β-glucose while the peak at 92 ppm represents α-glucose.7 
It was expected that the spectra would show a lactic acid peak in Sample 6 and Sample 16 due 
to the cells undergoing lactic acid fermentation. However, this is not seen in those respective 
spectra’s. This could be due to the fact that the cells were not under completely anaerobic 
conditions, which allowed them to carry out aerobic respiration. If the cells were going through 
aerobic respiration, the labeled glucose would disappear as carbon dioxide released from the 
citric acid cycle, and thus the α-glucose and β-glucose peaks would show a decreased peak 
height (Since carbon dioxide is released as a gas, it cannot be picked up by NMR analysis so a 
peak will not be present). Unfortunately, this is not seen in Graphs 2 and 3 due to the fact that 
the amount of glucose increases. In future studies, the cells can be flushed with nitrogen gas to 
ensure completely anaerobic conditions. Also, the measurements can be made over a longer 
period of time, allowing the cells more time to undergo metabolism of glucose. 
 
 
Graph 4: Nonlinear Regression Plot for 20 mM Metformin 
 
Graph 5: Nonlinear Regression Plot for 3.3 mM Phenformin 
Table 5: Nonlinear Regression Analysis 
 Metformin Phenformin 
Concentration (mM) 20 3.3 
Vmax (µmol inosine/min/mL ADA) 28 28 
Km (µM) 31 31 
KI (mM) 88 10 
Mode of Inhibition Competitive Competitive 
 
It was determined that the Km value is equal to 31 µM. The KI for 20 mM metformin is 88 mM 
while the KI for 3.3 mM phenformin is 10 mM as seen in Table 3. Since both KI values are larger 
than the Km, it can be assumed that the inhibitors reduce the binding affinity of the enzyme. 
Phenformin has a smaller KI value than metformin indicating that it is better at inhibiting ADA 
activity. The Vmax values are very similar; therefore, it can be said that the total amount of 
substrate being converted into product is similar in all three cases. This suggests that the 
inhibitor reduces the affinity of the enzyme for the substrate but does not decrease the ability 
of the enzyme to convert substrate into product if the substrate were to bind to it. Thus, the 
mode of inhibition of metformin and phenformin is competitive. The actual substrate binds 
tighter to the enzyme than either inhibitor is able to, implying that a subtle competitive 
inhibition is taking place. 
 
CONCLUSION 
In conclusion, it has been determined by nonlinear regression analysis that ADA activity is 
competitively inhibited by metformin and phenformin. However, the competitive inhibition is 
subtle due to the fact that the adenosine substrate has a higher binding affinity toward ADA in 
a comparison to the inhibitors, metformin and phenformin. As for the experiment involving 
glucose transporters in Lactobacillus acidophilus, the NMR results were inconclusive due to the 
lack of a peak representing lactic acid, initially suggesting that aerobic respiration was taking 
place. However, the amount of glucose seen in the spectrum did not decrease as should be 
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